Liou, Theodore G.
Kartsonaki, Christiana
Keogh, Ruth H.
Adler, Frederick R.
Article History
Received: 22 January 2020
Accepted: 2 April 2020
First Online: 20 April 2020
Competing interests
: During the course of the study, Theodore G. Liou received other support for performing clinical trials from Abbvie, Inc; CFF Therapeutics, Inc.; Corbus Pharmaceuticals Holdings, Inc; Genentech, Inc; Gilead Sciences, Inc.; Laurent Pharmaceuticals, Inc; Nivalis Therapeutics, Inc; Novartis Pharmaceuticals; Proteostasis Therapeutics, Inc; Savara, Inc; and Vertex Pharmaceuticals, Inc. Christiana Kartsonaki received support from the UK Medical Research Council. Ruth H. Keogh was supported by a UK Medical Research Council Fellowship (grant MR/M014827/1). Frederick R. Adler received other support from the National Science Foundation (grant EMSW21-RTG). The sponsors of clinical trials and funders of other support played no roles in the current study.